| Title |
A Phase III, multi-center, randomized, double-blind, 48 week study to evaluate the safety and efficacy of osilodrostat in patients with Cushing's disease |
| Description |
A Phase III, multi-center, randomized, double-blind, 48 week study with an initial 12 week placebo-controlled period to evaluate the safety and efficacy of osilodrostat in patients with Cushing's disease. The study aimed to demonstrate the superiority of osilodrostat compared to placebo in achieving a complete response at Week 12, to evaluate the safety of osilodrostat compared to placebo, and to evaluate the long-term safety and efficacy of osilodrostat. |
| Organism |
Homo sapiens |
| Data Type |
Other Type of Metabolome Data |
| Data Accessibility |
Controlled-access |
| BioProject |
PRJCA015654 |
| Release Date |
2023-04-13 |
| Submitter |
Xiao Hui Guo (bdyyguoxiaohui@sina.com) |
| Organization |
Peking University First Hospital |
| Submission Date |
2023-03-22 |